8-K: Xeris Biopharma Files Patent Infringement Lawsuits

Xeris Biopharma Holdings, Inc. has filed patent infringement lawsuits against multiple defendants concerning its KEVEYIS (dichlorphenamide) product.

Summary

• Xeris Biopharma Holdings, Inc., through its subsidiary Xeris Pharmaceuticals, Inc., has initiated patent infringement lawsuits.
• The lawsuits were filed on October 13, 2026, in the U.S. District Court for the District of New Jersey.
• Defendants include Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, Lemed Specialty Pharmacy Arizona, LLC, Rising Pharma Holdings, Inc., and Rising Pharma Specialties Pvt. Ltd.
• The litigation centers around U.S. Patent No. 12,758,502 (the 502 patent), which is related to the company's KEVEYIS (dichlorphenamide) product.
• The company alleges that the defendants will infringe the 502 patent by making, using, selling, offering for sale, and/or importing their generic dichlorphenamide products.
• Xeris Biopharma is seeking a judgment of infringement, injunctive relief, monetary damages, enhanced damages, attorneys' fees, and costs.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative development due to the initiation of patent litigation, which can be costly and uncertain, despite the company's efforts to protect its intellectual property.

Positives

• Proactive protection of intellectual property related to the KEVEYIS product.
• Seeking to prevent infringement of the 502 patent, which could safeguard future revenue streams.

Negatives

• Initiation of costly and time-consuming patent litigation.
• Uncertainty of outcome in legal proceedings.
• Potential for significant legal expenses and diversion of management resources.

Risks

• The outcome of the patent infringement lawsuits is uncertain and could result in unfavorable judgments.
• The litigation process may be lengthy and expensive, impacting financial resources.
• Potential for generic competitors to continue or expand their market presence if the patent is not successfully defended.
• The company may face counterclaims or challenges to the validity of the 502 patent.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. The future outlook is contingent on the outcome of the patent litigation.

Management Comments

• The Company is seeking a judgment of infringement, injunctive relief prohibiting further infringement, monetary damages adequate to compensate for the infringement, enhanced damages where permitted by law, attorneys fees, costs, and such other relief as the court deems appropriate.

Industry Context

StockSavvy.ai notes that patent litigation is a common strategy in the pharmaceutical industry to protect market exclusivity for branded drugs against generic competition. The success of such litigation can significantly impact a company's revenue and market share.

Legal Proceedings

• Patent infringement lawsuits filed against Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, and Lemed Specialty Pharmacy Arizona, LLC.
• Patent infringement lawsuits filed against Rising Pharma Holdings, Inc. and Rising Pharma Specialties Pvt. Ltd.
• Litigation concerns U.S. Patent No. 12,758,502 related to KEVEYIS (dichlorphenamide) product.
• Allegations include infringement by making, using, selling, offering for sale, and/or importing generic dichlorphenamide products.

Stakeholder Impact

• Shareholders: Potential for increased legal costs and uncertainty regarding the protection of KEVEYIS revenue streams.
• Competitors: The litigation may deter other generic manufacturers from entering the market with dichlorphenamide products.
• Patients: Continued availability of KEVEYIS and potential future generic alternatives may be affected by the litigation outcome.

Next Steps

• Pursue legal action to obtain a judgment of infringement.
• Seek injunctive relief to prohibit further infringement.
• Seek monetary damages, enhanced damages, attorneys' fees, and costs.

Key Dates

Recommendation

The initiation of patent litigation introduces significant uncertainty and potential costs, which could negatively impact the stock price in the short term. While protecting intellectual property is crucial, the outcome is not guaranteed. Therefore, a 'hold' position is recommended pending further developments in the legal proceedings.

Keywords

patent infringement, KEVEYIS, dichlorphenamide, pharmaceuticals, litigation, intellectual property, generic drugs